Carbachol, also known as carbamylcholine and sold under the brand name Miostat among others, is a cholinomimetic drug that binds and activates acetylcholine receptors. Thus it is classified as a cholinergic agonist. It is primarily used for various ophthalmic purposes, such as for treating glaucoma, or for use during ophthalmic surgery. It is generally administered as an ophthalmic solution (i.e., eye drops).
Carbachol produces effects comparable to those of sarin if a massive overdose is administered (as may occur following industrial and shipping accidents) and therefore it is classified as an extremely hazardous substance in the United States as defined in Section 302 of the U.S. Emergency Planning and Community Right-to-Know Act (42 U.S.C. 11002), and is subject to strict reporting requirements by facilities which produce, store, or use it in significant quantities.
It is on the World Health Organization's List of Essential Medicines.
Carbachol is a choline carbamate and a positively charged quaternary ammonium compound. It is not well absorbed in the gastro-intestinal tract and does not cross the blood–brain barrier. It is usually administered topical ocular or through intraocular injection. Carbachol is not easily metabolized by cholinesterase, it has a 2 to 5 minute onset of action and its duration of action is 4 to 8 hours with topical administration and 24 hours for intraocular administration. Since carbachol is poorly absorbed through topical administration, benzalkonium chloride is mixed in to promote absorption.
Carbachol is a parasympathomimetic that stimulates both muscarinic and nicotinic receptors. In topical ocular and intraocular administration its principal effects are miosis and increased aqueous humour outflow.
In the cat and rat, carbachol is well known for its ability to induce rapid eye movement (REM) sleep when microinjected into the pontine reticular formation. Carbachol elicits this REM sleep-like state via activation of postsynaptic muscarinic cholinergic receptors (mAChRs).
Cette page est générée automatiquement et peut contenir des informations qui ne sont pas correctes, complètes, à jour ou pertinentes par rapport à votre recherche. Il en va de même pour toutes les autres pages de ce site. Veillez à vérifier les informations auprès des sources officielles de l'EPFL.
Ce cours permet aux étudiants ayant suivi Morphologie I de réviser et d'approfondir leurs connaissances par l'étude de l'anatomie radiologique et du développement. L'origine de malformations fréquente
Explore la pharmacologie du système nerveux autonome et les effets des médicaments.
Couvre la synapse cholinergique et adrénergique, les effets des neurotransmetteurs, la classification des récepteurs et les applications cliniques.
Couvre la pharmacologie de la toxine botulique et de la myasthénie gravis maladie auto-immune.
Le récepteur nicotinique de l’acétylcholine est un récepteur ionotrope perméable aux ions sodium ainsi qu'aux ions potassium (canal cationique non spécifique), sensible à l'acétylcholine. Il tient son nom de l'un de ses agonistes, la nicotine, par opposition aux récepteurs muscariniques (récepteurs métabotropes). Il fait partie de la super-famille des récepteurs-canaux nicotinoïdes.
A nicotinic agonist is a drug that mimics the action of acetylcholine (ACh) at nicotinic acetylcholine receptors (nAChRs). The nAChR is named for its affinity for nicotine. Examples include nicotine (by definition), acetylcholine (the endogenous agonist of nAChRs), choline, epibatidine, lobeline, varenicline and cytisine. Nicotine has been known for centuries for its intoxicating effect. It was first isolated in 1828 from the tobacco plant by German chemists Posselt and Reimann.
thumb|Schéma d'un récepteur muscarinique. Un récepteur muscarinique est un récepteur métabotrope qui lie l'acétylcholine libérée dans le milieu extracellulaire. Les récepteurs muscariniques présentent : M1, M2, M3, M4 et M5. Cette liaison entraîne soit une inhibition de l'adénylate cyclase, ce qui diminue la concentration intracellulaire en AMP cyclique, soit une activation de la phospholipase C (PLC), provoquant une augmentation de la concentration intracellulaire de diacylglycérol (DAG) et d'inositol triphosphate (IP3).
It has been suggested already more than 60 years ago to use polarized nuclei in particle scattering experiments1, but only with the discovery of the solid effect dynamic nuclear polarization process2 the realisation of polarized solid targets became possib ...